Brett Carlson, MD
Cardiovascular Disease · Mason City, IANPI 1992975791
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,717 of the $2,366 with a category attached, or 72.6%. 3 manufacturers reported payments, led by Abbott at 52.6% of the total. Reporting peaked in 2022 at $1,331 and has fallen 73.5% since, to $353 in 2023.
Across 60 payments — averaging $39.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$1K
- Medtronic$1K
- Boston Scientific$20
What the payments were for
- Travel & lodging$64927%
- Food & beverage$1,71773%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 13 | $1,245 |
| Medtronic(2 entities) | 46 | $1,101 |
| Boston Scientific | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$812
- COREVALVE EVOLUT R$325
How this compares
$2,366 in reported general payments places this provider in the 65th percentile of 142 cardiovascular disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 127 | $169,458 |
| Repatha SureclickEvolocumab | 38 | $48,909 |
| XareltoRivaroxaban | 18 | $26,920 |
| JardianceEmpagliflozin | 12 | $16,720 |
| Praluent PenAlirocumab | 11 | $12,310 |
| Metoprolol Succinate | 250 | $5,347 |
| Atorvastatin Calcium | 159 | $2,920 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 47 | $892 |
| Losartan Potassium | 54 | $818 |
| Flecainide Acetate | 15 | $801 |
| Rosuvastatin Calcium | 77 | $758 |
| Amlodipine Besylate | 68 | $624 |
| ClopidogrelClopidogrel Bisulfate | 26 | $547 |
| Ezetimibe | 29 | $440 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 13 | $401 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Mason City
- Sepideh DarbandiMason City$9K
- Noor SubahMason City$8K
- Tauseef AkhtarMason City$8K
- Michael SpoonerMason City$7K
- Radu HagauMason City$3K
- Brian OlshanskyIowa City$219K
- Troy HounshellWest Des Moines$164K
- Enrico MartinWest Des Moines$113K
- Gursukhman Deep SidhuDavenport$60K
- Suzanne FeigofskyWest Des Moines$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.